DesigneRx Pharmaceuticals, Inc. (DRX) a subsidiary of Polaris Pharmaceuticals, Inc., is a therapeutic protein drug manufacturer located in Vacaville, California. DRX has a cGMP facility to produce novel protein therapeutics to support clinical trials at various stages in the USA, Europe, and the Asian-Pacific region. PEGylated Arginine Deiminase (ADI-PEG 20), the lead project of the company is now in clinical trials for patients with hepatocellular carcinoma, mesothelioma, pancreatic cancer and other cancer indications. DRX manufactures all drugs for global clinical studies conducted by Polaris Pharmaceuticals, Inc.